{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:17:54Z","timestamp":1769757474443,"version":"3.49.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Autonomic symptoms are among the most important factors determining the quality of life in patients with Parkinson\u2019s disease (PD). This study aimed to assess the profile of autonomic dysfunction symptoms in three groups of patients with genetic PD, carrying mutations in <jats:italic>GBA<\/jats:italic>, <jats:italic>LRRK2<\/jats:italic>, and <jats:italic>PRKN<\/jats:italic> genes, compared with subjects with sporadic PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This case\u2013control observational secondary analysis of prospectively collected data was performed on 742 patients (485 in the sporadic group, 165 in the LRRK2 group, 85 in the GBA group, and nine in the PRKN group). Autonomic symptoms were evaluated using the Scale for Outcomes in Parkinson\u2019s Disease-Autonomic (SCOPA-AUT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The GBA group exhibited more severe autonomic linsymptoms than the sporadic group, even after controlling for potential confounders such as disease duration and levodopa equivalent daily dose (linear regression B value\u202f=\u202f\u22124.668; Total SCOPA-AUT: <jats:italic>p<\/jats:italic>\u202f=\u202f0.050; LEDD: <jats:italic>p<\/jats:italic>\u202f=\u202f0.966; Disease Duration: <jats:italic>p<\/jats:italic>\u202f=\u202f0.498). The LRRK2 group initially showed more autonomic symptoms, but this did not remain significant after adjustment for disease duration (<jats:italic>B<\/jats:italic> value\u202f=\u202f\u22123.105; <jats:italic>p<\/jats:italic>\u202f=\u202f0.189). The PRKN group did not differ significantly from the sporadic group. Subgroup analysis highlighted specific issues including constipation, early satiety, and heat intolerance in both the GBA and LRRK2 groups, orthostatic hypotension in the GBA group and urinary incontinence and excessive perspiration in the LRRK2 group. Despite these subjective reports, objective assessment for orthostatic hypotension revealed no significant inter-group differences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings that genetic background may influence the severity of autonomic dysfunction in PD. In particular, patients with <jats:italic>GBA<\/jats:italic> mutations appear to experience a greater autonomic symptom burden, underscoring the need for personalized clinical monitoring and further research into genotype-specific disease progression. However, inconsistencies between subjective reports and objective autonomic measures emphasize the importance of employing more refined and sensitive assessment tools. Larger and demographically balanced cohorts are required to confirm these results, especially for the underpowered PRKN.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1657824","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:03:23Z","timestamp":1755605003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative study of autonomic dysfunction between Parkinson\u2019s disease with LRRK2, PRKN, and GBA mutations"],"prefix":"10.3389","volume":"16","author":[{"given":"B\u00e1rbara","family":"Maldotti Dalla Corte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayron","family":"Medeiros Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eur\u00edpedes Gomes","family":"de Carvalho Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Roberto","family":"de Mello Rieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-3-211-45295-0_47","article-title":"Parkinson\u2019s disease: premotor clinico-pathological correlations","volume":"70","author":"Wolters","year":"2006","journal-title":"J Neural Transm"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.91","article-title":"Non-motor features of Parkinson\u2019s disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14656566.2020.1713097","article-title":"State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson\u2019s disease","volume":"21","author":"Quarracino","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10286-020-00684-3","article-title":"Dysautonomia in early Parkinson disease: a window into the determinants of functional disability and an opportunity for early intervention","volume":"30","author":"Merola","year":"2020","journal-title":"Clin Auton Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1055\/s-0040-1713844","article-title":"Autonomic dysfunction in the synucleinopathies","volume":"40","author":"Coon","year":"2020","journal-title":"Semin Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson\u2019s disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s13760-020-01473-5","article-title":"Genetics of Parkinson\u2019s disease","volume":"120","author":"Cherian","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/genes12071006","article-title":"The genetics of Parkinson\u2019s disease and implications for clinical practice","volume":"12","author":"Day","year":"2021","journal-title":"Genes"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson\u2019s disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin Geriatr Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res Rev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","first-page":"83","article-title":"Updates on the genetics of Parkinson\u2019s disease: clinical implications and future treatment","volume":"30","author":"Chu","year":"2021","journal-title":"Acta Neurol Taiwanica"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of Glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fnins.2022.842498","article-title":"Dysautonomia in Parkinson\u2019s disease: impact of Glucocerebrosidase gene mutations on cardiovascular autonomic control","volume":"16","author":"Carandina","year":"2022","journal-title":"Front Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa dose equivalency in Parkinson\u2019s disease: updated systematic review and proposals","volume":"38","author":"Jost","year":"2023","journal-title":"Mov Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","article-title":"Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT","volume":"19","author":"Visser","year":"2004","journal-title":"Mov Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and Clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14253\/acn.2023.25.2.66","article-title":"Diagnosis and management of neurogenic orthostatic hypotension","volume":"25","author":"Ju","year":"2023","journal-title":"Ann Clin Neurophysiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"598446","DOI":"10.3389\/fcell.2020.598446","article-title":"Current evidence for a bidirectional loop between the lysosome and alpha-Synuclein Proteoforms","volume":"8","author":"Wildburger","year":"2020","journal-title":"Fronti Cell Dev Biol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.clinph.2020.11.024","article-title":"Electrodiagnostic assessmentof the autonomic nervous system: a consensus statement endorsed by the American autonomic society, American Academy of Neurology, and the international federation of clinical neurophysiology","volume":"132","author":"Cheshire","year":"2021","journal-title":"Clin Neurophysiol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1657824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:03:24Z","timestamp":1755605004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1657824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":28,"alternative-id":["10.3389\/fneur.2025.1657824"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1657824","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"1657824"}}